Our CRO services in NASH

Accelerate your drug development by exploring clinical endpoints in our
validated and biopsy-confirmed mouse models of NASH

Gubra DIO-NASH model

  • Prolonged diet-induced obese mouse model of NASH
  • Wild-type C57BL/6J mice fed GAN diet high in fat, fructose and cholesterol for ≥28 weeks before study start.
  • Biopsy-confirmed hepatosteatosis and fibrosis
  • Moderate metabolic disease
  • Clinical histopathological scoring (pre-to-post)

Gubra ob/ob-NASH model

  • Accelerated obese diet-induced mouse model of NASH
  • Leptin-deficient ob/ob mice fed GAN diet high in fat, fructose and cholesterol for 6-12 weeks before study start
  • Biopsy-confirmed hepatosteatosis and fibrosis
  • Severe metabolic disease
  • Clinical histopathological scoring (pre-to-post)

CDAA-HFD rodent models of NASH

  • CDAA diet high in fat, fructose and cholesterol for up to 20 weeks
  • Non-obesity without metabolic disease
  • Early onset of steatosis and fibrosis
  • Fast disease progression to bridging fibrosis (stage F3)
  • Clinical histopathological endpoints
  • Prophylactic and therapeutic drug efficacy

GAN-CCL4 rodent models of NASH

  • GAN diet high in fat, fructose and cholesterol in combination with CCL4 for up to 12 weeks
  • Non-obesity without metabolic disease
  • Early onset of steatosis and fibrosis
  • Fast disease progression to advanced fibrosis and cirrhosis.
  • Clinical histopathological endpoints
  • Prophylactic evaluation of drug efficacy

AI-assisted NASH histopathology using GHOST

At Gubra, we have developed the deep learning-based app GHOST (Gubra Histopathological Objective Scoring Technology) to automatically perform complete NAFLD Activity Score (NAS) and Fibrosis Staging in liver biopsies with additional quantitative metrics.

Gubra in vivo study approach

Our DIO-NASH mice are always ready and available for rapid onset of efficacy studies.

Pre- and post-liver biopsies allow for stratification of disease severity at baseline and improves detection of drug treatment efficacy.

All animals enrolled into study groups demonstrate histology-proven hepatosteatosis and fibrosis.

 

Related Links:

Main offerings

 

  • Metabolic assessment (body weight, adiposity, food intake, glycemic control and glucose tolerance)
  • Biochemical assessment for plasma lipids and liver biomarkers
  • Biochemical assessment for hepatic lipid, inflammation and collagen content
  • Histomorphomtric assesment for hepatic steatosis, inflammation, hepatocellular ballooning and fibrosis
  • Histopathological scoring for NAFLD Activity Score and Fibrosis Stage
  • Deep learning AI
  • RNA sequencing and bioinformatics
  • Flow cytometry

Get in touch

Please get in touch if you are interested in discussing how to get started with your study.

Michael Feigh

Director

mfe@gubra.dk
+45 2382 9493